NCT05132582 2026-03-16
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT05113251 2026-02-23
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT02320435 2026-02-12
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07386938 2026-02-04
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
R-Pharm
Phase 3 Active not recruiting
NCT04208178 2026-02-02
EPIK-B2
Novartis
Phase 3 Active not recruiting
NCT05296798 2026-01-16
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04193059 2025-11-26
PANSY
Fudan University
Phase 3 Active not recruiting
NCT04514419 2025-11-21
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
BioRay Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT02625441 2025-02-11
BOLD-1
Helsinki University Central Hospital
Phase 3 Active not recruiting
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting
NCT01996267 2024-03-29
TRAIN-2
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT03595592 2024-03-06
APTneo
Fondazione Michelangelo
Phase 3 Active not recruiting